Gun­ning for 2023 ap­proval, GSK de­tails PhI­II da­ta for Jem­per­li in front­line en­dome­tri­al can­cer

GSK has a new slate of da­ta to of­fer on its PD-1 in­hibitor, Jem­per­li — da­ta that the phar­ma gi­ant hopes will ce­ment one of the four drug ap­provals it’s ex­pect­ing this year.

While Jem­per­li (dostar­limab) is al­ready ap­proved for a sub­set of pa­tients with sec­ond-line en­dome­tri­al can­cer, GSK set out in the Phase III RU­BY tri­al to test it as an ear­li­er line of treat­ment while al­so en­rolling a broad­er group of pa­tients. In an in­ter­im analy­sis, Jem­per­li was shown to ex­tend pro­gres­sion-free sur­vival for both the sub­set and the over­all tri­al pop­u­la­tion when added to chemother­a­py.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN